nabriva.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
https://www.nabriva.com/sitemap.xml User-agent: * | ||
Meta Tags
| Title | Commercial Stage Biopharmaceutical Company | |
| Description | Driven to Deliver Innovative Treatments for Patients With Infectious Nabriva is a commercial-stage biopharmaceutical company engaged in the research & development of novel antibiotics to treat serious infections, with a current focus on the pleuromutilin class of antibiotics. Learn more at |
| Keywords | Commercial stage biopharmaceutical company, medications for infectious diseases, new antibiotics |
Server Information
| WebSite | |
| Host IP | 52.176.165.69 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
nabriva.com Valuation
|
US$19,174,775
Last updated: 2023-04-29 04:12:22
nabriva.com has Semrush global rank of 551,991. nabriva.com has an estimated worth of US$ 19,174,775, based on its estimated Ads revenue. nabriva.com receives approximately 2,212,474 unique visitors each day. Its web server is located in United States, with IP address 52.176.165.69. According to SiteAdvisor, nabriva.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$19,174,775 |
| Daily Ads Revenue | US$17,700 |
| Monthly Ads Revenue | US$530,994 |
| Yearly Ads Revenue | US$6,371,926 |
| Daily Unique Visitors | 147,499 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| nabriva.com. | A | 43199 | IP: 52.176.165.69 |
| nabriva.com. | NS | 86400 | NS Record: dns2.cscdns.net. |
| nabriva.com. | NS | 86400 | NS Record: dns1.cscdns.net. |
| nabriva.com. | MX | 86400 | MX Record: 10 eu-smtp-inbound-2.mimecast.com. |
| nabriva.com. | MX | 86400 | MX Record: 10 eu-smtp-inbound-1.mimecast.com. |
| nabriva.com. | TXT | 3600 | TXT Record: v=spf1 include:eu._netblocks.mimecast.com include:emailus.freshservice.com -all |
| nabriva.com. | TXT | 3600 | TXT Record: MS=ms33401695 |
| nabriva.com. | TXT | 300 | TXT Record: apple-domain-verification=dAGHCUig4EdotSow |
| nabriva.com. | TXT | 86400 | TXT Record: nabcorp01.azurewebsites.net |
HtmlToTextCheckTime:2023-04-29 04:12:22
| Go to... Home About Nabriva Our Products Named Patient Program Meet the Team pipeline & research Fosfomycin pleuromutilins For Investors Events & Presentations Press Releases Financial Performance Share Performance Shareholder Information Corporate Governance News & Publications careers contact us Nabriva US News & Publications Careers Contact Us Home About Nabriva Our Products Named Patient Program Meet the Team pipeline & research Fosfomycin pleuromutilins For Investors Events & Presentations Press Releases Financial Performance Share Performance Shareholder Information Corporate Governance News & Publications careers contact us Site Web Search --> MEDICAL PROFESSIONALS - REGISTER NOW Click here to learn more about Xenleta™ (lefamulin) for both Oral and IV Use | FDA Approves Xenleta TM (lefamulin) for both Oral and IV Use ––> --> Driven to Deliver Innovative Treatments for Patients With Infectious Diseases Nabriva Therapeutics is a commercial-stage |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 0 Content-Type: text/html; charset=UTF-8 Location: https://nabriva.com/ Date: Fri, 22 Oct 2021 02:53:57 GMT HTTP/1.1 200 OK Cache-Control: public Content-Length: 34706 Content-Type: text/html; charset=utf-8 Set-Cookie: dnn_IsMobile=False; path=/; HttpOnly Set-Cookie: language=en-US; path=/; HttpOnly Set-Cookie: .ASPXANONYMOUS=i2mt1DI-eh2PtMPKUXb3URkCrkW61hxc3jk0jhlBsOGps7HSGCw6nS26xOpSe6AlwaU2dP4pweVVHsVUOutibhh_ke2M9OACu2Lipx7mMBIaBbjX0; expires=Thu, 30-Dec-2021 13:33:57 GMT; path=/; HttpOnly Set-Cookie: __RequestVerificationToken=kt9AK8OaG4e9nLkVyX9jbgr68Rq3fchWrvA_ajLTLVT3lcH28_EQlOLeAPk246tpb1zO1w2; path=/; HttpOnly X-UA-Compatible: IE=edge X-XSS-Protection: 1; mode=block X-Frame-Options: SAMEORIGIN Set-Cookie: ARRAffinity=d0c153f95751e5a67027b7f2b51f81b302c481d8d664650fbf36469568d8c4b5;Path=/;HttpOnly;Secure;Domain=nabriva.com Set-Cookie: ARRAffinitySameSite=d0c153f95751e5a67027b7f2b51f81b302c481d8d664650fbf36469568d8c4b5;Path=/;HttpOnly;SameSite=None;Secure;Domain=nabriva.com Date: Fri, 22 Oct 2021 02:53:57 GMT |
nabriva.com Whois Information
Domain Name: NABRIVA.COM Registry Domain ID: 324987402_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2021-01-19T06:09:15Z Creation Date: 2006-01-23T21:20:36Z Registry Expiry Date: 2022-01-23T21:20:36Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: DNS1.CSCDNS.NET Name Server: DNS2.CSCDNS.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-10T20:16:39Z <<< |